“…These include mouse models of Collagen VI- (Noguchi et al, 2017;Mohassel et al, 2018), human DMD (Uezumi et al, 2014) and mouse models of DMD (Box 1) (Uezumi et al, 2011;Mozzetta et al, 2013;Lemos et al, 2015;Contreras et al, 2016Contreras et al, , 2020Ieronimakis et al, 2016;Kopinke et al, 2017;Mázala et al, 2020;Reggio et al, 2020;Giuliani et al, 2021), Facioscapulohumeral dystrophy (FSHD) (Bosnakovski et al, 2017(Bosnakovski et al, , 2020, Limb-girdle muscular dystrophy (LGMD) (Hogarth et al, 2019), and ALS neuromuscular disease (Gonzalez et al, 2017;Madaro et al, 2018). Increased muscle fibrosis and FAP expansion also occur after single and repeated cycles of intramuscular BaCl 2 , notexin, cardiotoxin, or glycerol administrations (Uezumi et al, 2010;Dadgar et al, 2014;Pessina et al, 2014;Contreras et al, 2016Contreras et al, , 2020Theret et al, 2021), vastus medialis muscles of compromised knee osteoarthritis patients (Ikemoto- Uezumi et al, 2017), human anterior cruciate ligament injuries (Fry et al, 2017), induced hindlimb ischemia (Santini et al, 2020), degenerated muscles of type 2 diabetic patients (Farup et al, 2020), obesity-mediated diaphragm dysfunction of chronic high-fat diet-fed mice (Buras et al, 2019), and surgical muscle traumas including denervation and laceration (Brandan et al, 1992;Pessina et al, 2014;Contreras et al, 2016;Madaro et al, 2018;Rebolledo et al, 2019). Muscle-resident FAP...…”